124 related articles for article (PubMed ID: 9076480)
1. Oral bropirimine immunotherapy of rodent prostate cancer.
Sarosdy MF
Eur Urol; 1997; 31 Suppl 1():5-9. PubMed ID: 9076480
[TBL] [Abstract][Full Text] [Related]
2. In vivo antitumor activity of bropirimine against PAIII and Dunning MAT-LyLu rodent prostate cancers.
Sarosdy MF; Higdon AL; Demoor CA
J Urol; 1996 Jun; 155(6):2085-9. PubMed ID: 8618341
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of oral administration of an interferon-inducing pyrimidinone, Bropirimine, on murine renal-cell carcinoma.
Fujioka T; Ishikura K; Hasegawa M; Ogyu K; Matsushita Y; Sato M; Sato F; Aoki H; Kubo T
Cancer Chemother Pharmacol; 1995; 36(1):7-12. PubMed ID: 7536641
[TBL] [Abstract][Full Text] [Related]
4. Protection from carcinogen-induced murine bladder carcinoma by interferons and an oral interferon-inducing pyrimidinone, bropirimine.
Borden EC; Sidky YA; Ertürk E; Wierenga W; Bryan GT
Cancer Res; 1990 Feb; 50(4):1071-4. PubMed ID: 2297754
[TBL] [Abstract][Full Text] [Related]
5. Bropirimine, an orally active anticancer agent for superficial bladder cancer.
Akaza H; Kotake T; Machida T
Eur Urol; 1998 Aug; 34(2):107-10. PubMed ID: 9693244
[TBL] [Abstract][Full Text] [Related]
6. [In vitro direct antiproliferative activity and in vivo antitumor activity of bropirimine against bladder cancer].
Tahara M; Nomura S; Takahashi M; Takagi H; Hashimoto M; Eto H; Kamidono S
Gan To Kagaku Ryoho; 1996 Jul; 23(8):1039-44. PubMed ID: 8687218
[TBL] [Abstract][Full Text] [Related]
7. Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial.
Sarosdy MF; Lowe BA; Schellhammer PF; Lamm DL; Graham SD; Grossman HB; See WA; Peabody JO; Moon TD; Flanigan RC; Crawford ED; Morganroth J
Urology; 1996 Jul; 48(1):21-7. PubMed ID: 8693646
[TBL] [Abstract][Full Text] [Related]
8. A study on direct antitumor activity of bropirimine (oral interferon inducer) for renal cell carcinoma.
Onishi T; Machida T
Hinyokika Kiyo; 1994 Mar; 40(3):195-200. PubMed ID: 8178735
[TBL] [Abstract][Full Text] [Related]
9. Bropirimine as neoadjuvant therapy decreases residual disease and expression of markers PCNA and TGF-beta 1 in a rat orthotopic prostate adenocarcinoma.
Lievano G; Di Domenico D; Brown J; Bridges P; Rubenstein M; Shaw M; Guinan P
Methods Find Exp Clin Pharmacol; 1997 May; 19(4):261-7. PubMed ID: 9228652
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antitumor activity of the interferon inducer bropirimine.
Shimizu M; Oh-Hashi F; Tsukagoshi S; Iwaguchi T; Kataoka T
Anticancer Drugs; 1995 Feb; 6(1):158-62. PubMed ID: 7756678
[TBL] [Abstract][Full Text] [Related]
11. [Bropirimine (U-54461S) late phase II clinical study for carcinoma in situ of the bladder. Japan Bropirimine Study Group].
Akaza H; Shimazaki J; Tashiro K; Kotake T; Okajima E; Kagawa S; Machida T
Gan To Kagaku Ryoho; 1997 Jan; 24(1):77-85. PubMed ID: 9020949
[TBL] [Abstract][Full Text] [Related]
12. [Bropirimine (U-54461S) early phase II clinical studies--to investigate the efficacy and safety of bropirimine treatment on various malignant tumors (urological, hematologic, and dermal cancers)].
Furue H; Machida T; Masaoka T; Ikeda S
Gan To Kagaku Ryoho; 1997 Jan; 24(1):67-75. PubMed ID: 9020948
[TBL] [Abstract][Full Text] [Related]
13. In vitro antitumor activity of bropirimine against urinary bladder tumor cells.
Tei Y; Matsuyama H; Wada T; Kurisu H; Tahara M; Naito K
Anticancer Res; 2002; 22(3):1667-71. PubMed ID: 12168852
[TBL] [Abstract][Full Text] [Related]
14. Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group.
Witjes WP; König M; Boeminghaus FP; Hall RR; Schulman CC; Zurlo M; Fittipaldo A; Riggi M; Debruyne FM
Eur Urol; 1999 Dec; 36(6):576-81. PubMed ID: 10559611
[TBL] [Abstract][Full Text] [Related]
15. Treatment of carcinoma in situ of the urinary bladder with bropirimine.
Witjes JA
Eur Urol; 1997; 31 Suppl 1():27-30. PubMed ID: 9076483
[TBL] [Abstract][Full Text] [Related]
16. Treatment of colon cancer in rats with rMuTNF and the interferon-inducer bropirimine.
Marquet RL; de Bruin RW; Eggermont AM; Jeekel J
Agents Actions; 1989 Jan; 26(1-2):151-2. PubMed ID: 2711933
[TBL] [Abstract][Full Text] [Related]
17. [Bropirimine (U-54461S) phase I clinical studies].
Furue H
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1941-9. PubMed ID: 8978802
[TBL] [Abstract][Full Text] [Related]
18. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
Li LH; DeKoning TF; Wallace TL
Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel, bropirimine and linomide: effect on growth inhibition in a murine prostate cancer model by different growth regulatory mechanisms.
Shaw M; Ratanawong S; Chou P; Ray V; Mirochnik Y; Slobodskoy L; Rubenstein M; Guinan P
Methods Find Exp Clin Pharmacol; 1998 Mar; 20(2):111-4. PubMed ID: 9604852
[TBL] [Abstract][Full Text] [Related]
20. A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tract.
Sarosdy MF
Eur Urol; 1997; 31 Suppl 1():20-6. PubMed ID: 9076482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
